The neutralisation and inhibitory effects of new tRNA-mimetic aptamer against cytotoxin-induced cytotoxicity in human skin keratinocytes

Cytotoxin (CTX) is the major venom toxin in cobra venom, accounting for the dermonecrosis in cobra envenomed patients. Conventional antibody-based antivenoms have limited efficacy in the treatment for CTX-manifested dermonecrosis, highlighting the urgent needs for discovery of new therapeutics. This study aims to discover oligonucleotide-based aptamers which target the functional epitopes of CTX to inhibit its cytotoxicity. Genomic tRNA Database (GtRNAdb) was acquired for the computational selection and design of potential tRNA-mimetic aptamers (AptRNAs) targeting CTX. The binding characteristics of the AptRNAs were further validated by electromobility shift assay (EMSA), and enzyme-linked oligonucleotide assay (ELONA). The best candidate was also examined for neutralisation potency and efficacy. The computational analyses identified six consensus AptRNA clusters, whereby three AptRNAs showed significant binding for CTX with an ascending ranking from AptRNA4 > AptRNA6 > AptRNA5. These AptRNAs bind to the functional epitopes of CTX. AptRNA6 had the highest binding specificity towards CTX, with a binding affinity (K D ) of 14.45 nM. Furthermore, AptRNA6 exhibited the best neutralisation and rescue potency in CTX-induced cytotoxicity. Even at low treatment concentrations, AptRNA6 also demonstrated the highest potency in rescuing experimental post-envenomed model by cobra venoms of medically important species. Overall, the findings concluded the potential of AptRNA6 as synthetic biotherapeutic against cobra venom CTX. • This study discovered tRNA-mimetic aptamer (AptRNA) as new biotherapeutic for CTX-induced toxicity. • We identified 3 potential AptRNAs with the best binding to functional epitopes of CTX. • AptRNA6 demonstrated the best neutralising potency and efficacy for CTX-induced cytotoxicity. • AptRNA6 has the potential as new synthetic biotherapeutic against cobra venom CTX.